rivaroxaban

(redirected from Xarelto)
Also found in: Medical.
Translations

rivaroxaban

n rivaroxabán m
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
ENPNewswire-September 3, 2019--Bayer - Xarelto 2.5 mg plus aspirin recommended for patients at high risk of heart attacks, strokes and death due to chronic coronary syndromes
The person is taking blood thinners, such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), fondaparinux sodium (Arixtra), or aspirin, or has a bleeding disorder.
The procedure can be performed in your doctor's office, but it is not suitable for people who take blood thinners, such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban (Savaysa).
It was reported yesterday that the contract has been signed to resolve litigation related to blood thinner medication, Xarelto. The two firms reached the settlement more than five years after the litigation started.
lawsuits over their blockbuster blood thinner Xarelto for a total of $775 million.
Bayer (BAYRY) announced that more than five years after the Xarelto litigation began, and with the company and Johnson & Johnson's (JNJ) Janssen Pharmaceuticals prevailing in all six cases that went to trial, the companies have reached an agreement in principle to settle in the amount of $775M.
The health care giant will begin with its popular blood thinner, Xarelto, said Scott White, head of J&J's North American pharmaceutical marketing.
Commonly ordered medications are Abilify, Advair Diskus, Celebrex, Crestor, Cymbalta, Entocort, Januvia, Lyrica, Nexium, Pradaxa, Premarin, Vytorin, and Xarelto.
He said innovative products such as the oral anticoagulant Xarelto, eye medicine Eylea, and oral cancer treatment Nexavar were the top products in the region.
Additional contributors to sales growth included STELARA ($4.0 billion, up 24%), INVEGA SUSTENNA/ XEPLION/TRINZA ($2.6 billion, +16%), ZYTIGA ($2.5 billion, +11%), and XARELTO ($2.5 billion, +10%), partially offset by declines in REMICADE (-10% to $6.3 billion) due to biosimilar entrants.
28, 2017, in BMJ, showed that the DOAC apixaban (Eliquis) was more effective than edoxaban (Savaysa), rivaroxaban (Xarelto), dabigatran (Pradaxa) and warfarin at preventing strokes, pulmonary emboli, heart attacks and death from all causes.